Given that ICI monotherapy may be ineffective in preventing recurrence when CD8+ T cells are suppressed by activation of the β-catenin signaling pathway, combination therapy with the anti-VEGF antibody bevacizumab can counteract that by abrogating VEGF-mediated immunosuppression and increasing tumor infiltration of T cells [135]. Here, CD8A is linked to neoplasm.